Lichen planopilaris (LPP) is a chronic inflammatory condition that destroys hair follicles and replaces them with scar tissue, causing permanent hair loss. It belongs to a group of conditions called primary cicatricial alopecias, and it is the most common lymphocyte-driven form within that group. The disease tends to affect middle-aged women most often, though men and people of any age can develop it. Because the scarring is irreversible once it occurs, early recognition and treatment matter enormously for preserving the hair that remains.
What Happens Inside the Hair Follicle
Each hair follicle contains a region called the bulge, where epithelial stem cells live. These stem cells are responsible for regenerating the hair through each growth cycle. Under normal circumstances, the bulge enjoys a form of immune protection that keeps inflammatory cells from attacking it. In LPP, that protection breaks down. Research shows that affected follicles lose the molecular signals that normally suppress immune recognition and instead start displaying markers that attract an immune response.1PubMed. Lichen planopilaris is characterized by immune privilege collapse of the hair follicle’s epithelial stem cell niche The result is a wave of T cells, particularly cytotoxic ones, that infiltrate the bulge and destroy the stem cells. Once those stem cells are gone, the follicle cannot produce new hair and collapses into scar tissue.
This pattern distinguishes LPP from another common form of inflammatory hair loss, alopecia areata, where the immune attack centers on the hair bulb, a deeper part of the follicle involved in active hair production rather than long-term stem cell storage.2British Journal of Dermatology. Differential expression of stem cell markers in lichen planopilaris and alopecia areata Because the bulb can recover, alopecia areata is usually reversible. LPP, by targeting the stem cells themselves, is not.
A second thread of research implicates a fat-metabolism pathway in the disease. Affected scalp tissue shows significantly decreased expression of a transcription factor called PPARγ, which helps maintain healthy oil glands and lipid balance around the follicle. When PPARγ drops, inflammatory lipids accumulate, oil glands shrink, and the whole hair-producing unit deteriorates. Mouse experiments confirmed that deleting PPARγ specifically in follicular stem cells produces a scarring hair-loss pattern that closely resembles LPP in humans.3PubMed Central. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia These two mechanisms, immune privilege collapse and PPARγ loss, likely work together rather than being separate causes.
Who Gets LPP and Why
LPP can appear at any age but most commonly shows up between the ages of 40 and 60, and the majority of affected people are women. The reasons for this sex and age skew remain unclear, though hormonal changes around menopause have been suggested as a contributing factor, particularly for the frontal fibrosing alopecia variant discussed below.
A genetic component seems to play a role. A study of LPP patients found that certain immune-system gene variants were dramatically overrepresented: roughly 62% of LPP patients carried a particular HLA allele compared with 21% of controls, and a related allele appeared in 70% of patients versus 33% of controls.4PubMed. Lichen planopilaris is associated with HLA DRB1*11 and DQB1*03 alleles These genes help determine which proteins the immune system recognizes as foreign, which fits the emerging picture of LPP as an autoimmune or autoimmune-like condition.
Environmental triggers have also been documented. Certain medications, including some biologic drugs used for inflammatory bowel disease, have been linked to LPP onset in case reports.5PubMed Central. Lichen planopilaris induced by infliximab: A case report And because LPP is related to lichen planus, a broader condition that can affect the skin, nails, and mucous membranes, some patients develop LPP alongside oral lichen planus or other lichen planus variants. Reports have documented oral disease appearing first and then LPP following months or years later, suggesting a shared underlying immune process that can migrate between tissues.
Early research into the scalp microbiome has added another layer. One study found a significant relationship between microbial populations on the scalp and the expression of inflammatory signaling molecules in LPP patients, suggesting that disruption of the normal microbial community may feed into the disease process.6PubMed Central. Lichen Planopilaris: The first biopsy layer microbiota inspection Whether this microbial imbalance is a cause, a consequence, or a bit of both remains an open question.7PubMed Central. The Gut and Skin Microbiome in Alopecia: Associations and Interventions
Recognizing LPP on the Scalp
LPP typically begins with scattered patches of hair loss on the scalp, often starting near the top or sides. The patches tend to be irregular and may expand slowly over months to years. Unlike common pattern hair loss, where thinning happens gradually across a broad area, LPP produces discrete bald spots where the skin looks smooth, pale, and slightly shiny because the follicular openings have been completely erased by scar tissue.
Active disease usually announces itself with symptoms before the hair loss becomes obvious. Scalp pain, burning, and tenderness, sometimes grouped under the term trichodynia, are common complaints. Around the edges of bald patches, you can often see redness and tiny scales wrapping around individual hairs, a finding called perifollicular erythema and perifollicular scaling. These signs indicate ongoing inflammation and active destruction.
Dermatologists use a magnifying tool called a dermatoscope (or trichoscope) to evaluate the scalp closely. The most frequently observed features in LPP are absence of follicular openings in the scarred areas, perifollicular scaling, white scarring patches, and perifollicular redness.8Dermatology Review/Przegląd Dermatologiczny. Trichoscopy in lichen planopilaris: an update In earlier stages, tubular casts around hair shafts and small branching blood vessels around follicles are particularly suggestive.9PubMed Central. Trichoscopic Features of Lichen Planopilaris versus Frontal Fibrosing Alopecia: A Systematic Review A punch biopsy of the scalp, examined under a microscope, remains the gold standard for confirming the diagnosis. The hallmark finding is a dense band of inflammatory cells hugging the upper portion of the follicle in a lichenoid pattern, sometimes accompanied by scarring that has replaced the follicle entirely.
LPP Subtypes
Classic LPP is the form described above: multifocal patches of scarring hair loss scattered across the scalp. But two major variants deserve separate mention because they look quite different clinically, even though the underlying pathology is the same.
Frontal fibrosing alopecia (FFA) has become dramatically more common over the past two decades, to the point where some dermatologists now see it more often than classic LPP. FFA causes a slow, progressive recession of the hairline along the forehead and temples, often with loss of eyebrows and sometimes body hair. Under the microscope, the inflammatory pattern is essentially identical to classic LPP.10PubMed. Frontal fibrosing alopecia versus lichen planopilaris: a clinicopathological study The rising incidence of FFA has sparked interest in environmental factors, since a genuine change in genetics cannot explain such a rapid increase. Sunscreen chemicals, fragrances, and other topical exposures have been investigated, though nothing definitive has emerged.
Graham-Little-Piccardi-Lassueur syndrome (GLPLS) is rare and defined by a triad of features: scarring alopecia on the scalp, non-scarring hair loss in the armpits and groin, and small spiny bumps on the trunk or scalp.11PubMed Central. Graham-little piccardi lassueur syndrome: an unusual variant of follicular lichen planus It predominantly affects women between 40 and 60 years old.12PubMed Central. Graham-Little-Piccardi-Lassueur Syndrome with Mucosal Involvement: A Rare Case Some patients with GLPLS also develop lichen planus lesions inside the mouth, further illustrating how widely the underlying immune process can range across the body.
Conditions That Mimic LPP
Scarring hair loss on the scalp has several potential causes, and telling them apart under the microscope can be genuinely tricky. The condition most often confused with LPP is discoid lupus erythematosus (DLE), another inflammatory process that scars follicles. Both show bands of lymphocytes around follicles, and both leave smooth, scarred patches. Clinically, DLE patches tend to be more defined and may have thicker scale, pigment changes, and follicular plugging, but overlap is common.
Researchers have worked to identify microscopic markers that can help distinguish the two. DLE tissue tends to contain significantly more of certain immune cells. One study found that a specific type of dendritic cell was present at roughly twice the density in DLE compared with LPP, and that clusters of more than 20 of these cells had perfect specificity for DLE, meaning they were never seen in LPP samples.13PubMed Central. Value of CD123 Immunohistochemistry and Elastic Staining in Differentiating Discoid Lupus Erythematosus from Lichen Planopilaris The pattern of elastic fiber destruction also differs: LPP typically shows a wedge-shaped loss, while DLE causes a more diffuse pattern.14Advances in Dermatology and Allergology. Dendritic cells may help differentiate discoid lupus erythematosus alopecia from lichen planopilaris Getting the diagnosis right matters because the two conditions respond to somewhat different treatments.
Treatment Options
No treatment can regrow hair where scar tissue has already replaced the follicle. The goal of therapy is to put the disease into remission, quiet the inflammation, and prevent further loss. Treatment choices depend on how active and widespread the disease is, and often involve a stepwise approach starting with milder options and escalating if needed.
Topical and Local Treatments
High-potency topical corticosteroids applied directly to the inflamed areas are usually the first line of defense, sometimes accompanied by injections of corticosteroid into active patches. Topical calcineurin inhibitors are another option in this category.15PubMed Central. Successful treatment of lichen planopilaris with topical cyclosporine: A case series These local treatments work best for limited disease and for maintaining remission after a flare has been controlled with systemic medication.
Platelet-rich plasma (PRP) injections have recently been studied as a procedural therapy. In a controlled trial comparing PRP to potent topical steroid, both reduced disease activity scores in the first two months, but the steroid group’s scores climbed back up by six months while the PRP group’s remained lower. Patient satisfaction was also significantly higher with PRP at the end of follow-up.16PubMed. Platelet-rich plasma as a new and successful treatment for lichen planopilaris: A controlled blinded randomized clinical trial This is still early evidence, but it suggests PRP could be a useful addition to the treatment toolkit.
Systemic Medications
When LPP is active, spreading, or not responding to topical measures, systemic therapies enter the picture. Hydroxychloroquine, an antimalarial drug with immunomodulatory properties, is among the most commonly used. One study found that it produced a significant reduction in disease activity scores in about 83% of patients after 12 months.17PubMed. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system In a retrospective series, roughly 41% of patients treated with hydroxychloroquine showed improvement, while only about 27% improved on doxycycline, a tetracycline antibiotic sometimes tried first because of its milder side-effect profile.18Archives of Dermatology. Lichen Planopilaris: Retrospective Study and Stepwise Therapeutic Approach Methotrexate and mycophenolate mofetil are other immunosuppressive options for cases that resist first-line therapy.
The PPARγ pathway has inspired a targeted treatment approach. Pioglitazone, a diabetes drug that activates PPARγ, has been used off-label for LPP. The rationale is that boosting PPARγ activity could counteract the lipid-metabolism breakdown and downstream inflammation seen in affected follicles.19Journal of the American Academy of Dermatology. The use of oral pioglitazone in the treatment of lichen planopilaris Results in published case series have been mixed but encouraging enough that some dermatologists include it as part of combination regimens.
JAK Inhibitors
Because the inflammatory cascade in LPP is driven heavily by interferon-gamma signaling and cytotoxic T cells, drugs that block the JAK-STAT signaling pathway have attracted considerable interest. Tofacitinib, a JAK inhibitor, showed measurable improvement in a case series of ten patients with stubborn LPP: disease activity scores dropped by roughly half on average, with individual reductions ranging from about 30% to over 90%.20PubMed Central. Tofacitinib for the treatment of lichen planopilaris: A case series However, a more rigorous randomized placebo-controlled trial found no significant difference in disease activity score reduction between tofacitinib and placebo.21PubMed. Efficacy and safety of tofacitinib in the treatment of adults with lichen planopilaris: A randomized placebo-controlled trial This kind of gap between open-label series and controlled trials is common in dermatology and suggests the evidence here is still early-stage. Reviews have noted that JAK inhibitors should be considered mainly for recalcitrant cases where other options have failed.22PubMed Central. JAK Inhibitors in the Treatment of Lichen Planopilaris
Tracking Disease Activity
One of the practical challenges of LPP is knowing whether treatment is actually working. The Lichen Planopilaris Activity Index (LPPAI) was developed for this purpose. It combines patient-reported symptoms like itching, pain, and burning with clinical signs such as redness, scaling, and a hair-pull test result, all rolled into a single numeric score.23PubMed Central. Clinical Efficacy and Safety of Methotrexate versus Hydroxychloroquine in Preventing Lichen Planopilaris Progress: A Randomized Clinical Trial A declining score over time generally indicates that treatment is suppressing disease activity. In practice, many dermatologists combine the LPPAI with repeat trichoscopy and clinical photos to gauge progress, since no single measure captures everything.
LPP tends to wax and wane. Some patients achieve a stable remission that lasts years; others relapse every time medication is tapered. There is currently no reliable way to predict who will have a self-limited course versus chronic progressive disease. This unpredictability is one of the most frustrating aspects for patients and clinicians alike.
Hair Transplantation After LPP
Once scarring has produced noticeable bald patches and the disease is quiescent, hair transplantation becomes a tempting option. The question is whether transplanted follicles can survive in tissue that has already demonstrated a capacity to destroy them. The evidence so far is not especially encouraging.
In a systematic review of LPP and FFA patients who received transplants, about 75% of LPP patients had positive short-term results over follow-up periods ranging from eight to 72 months.24PubMed. Hair Transplantation in Frontal Fibrosing Alopecia and Lichen Planopilaris: A Systematic Review But a more recent and larger systematic review painted a more sobering picture of long-term outcomes: among patients followed beyond two years, the vast majority had graft survival rates at or below 41%.25Anais Brasileiros de Dermatologia. Systematic review of efficacy of hair transplantation in patients with classic lichen planopilaris and frontal fibrosing alopecia: revisiting the current evidence Only a small number maintained survival rates in the 80-85% range. That is a stark gap between initial promise and lasting results.
Qualification criteria are strict. Most transplant protocols require that the disease be inactive for at least six months, and many prefer a longer quiet period.26PubMed Central. Hair Transplantation for Lichen Planopilaris: A Case Series of Five Patients Patients typically stay on immunomodulatory treatment before and after the procedure. Even with these precautions, the autoimmune process can reactivate and attack transplanted follicles. Transplantation remains an option in carefully selected cases, but setting realistic expectations about long-term density is important.
The Psychological Weight of Scarring Hair Loss
Hair loss from LPP carries a burden that extends well beyond cosmetics, and research has quantified just how significant it is. In a cross-sectional study of 87 patients with diffuse LPP, the average quality-of-life impairment score placed the disease in the “moderate” range, and about 40% of patients scored high enough to indicate severe impact on daily life. The hardest-hit areas were physical symptoms, leisure activities, and day-to-day tasks.27PubMed Central. Quality of Life in Patients with Diffuse Lichen Planopilaris: A Cross-Sectional Study of 87 Moroccan Cases Scalp pain and altered hair texture were the symptoms most strongly associated with impaired quality of life in that study.
Another study using both dermatology-specific and general mental-health questionnaires found that over 70% of LPP patients had moderate to extreme quality-of-life impairment, and roughly 63% were flagged as being at risk for psychological disorders. Younger patients, under 45, reported worse quality of life than older ones, and more active disease correlated with worse scores on both fronts.28PubMed Central. Quality of life and mental health status in patients with lichen planopilaris based on Dermatology Life Quality Index and General Health Questionnaire-28 questionnaires A systematic review confirmed the broader pattern: higher disease activity and severity tracked with more depression, more anxiety, and greater limitations in both physical and emotional roles.29Clinical and Experimental Dermatology. Quality-of-life assessment and the impact of early diagnosis and treatment in lichen planopilaris: a systematic review
These findings make a strong case for treating LPP aggressively and early, not only to preserve hair but to protect mental health. They also argue for screening LPP patients for anxiety and depression as part of routine care, something that does not happen consistently in practice.
Common Misconceptions
Several misunderstandings circulate about LPP that are worth clearing up. The first is that any scalp biopsy showing inflammation around a follicle means LPP. In reality, many conditions cause perifollicular inflammation, and the specific pattern, location on the follicle, and presence or absence of scarring all matter. The immune-cell profile and elastic-fiber pattern can help distinguish LPP from look-alikes like discoid lupus, as described earlier.
A second misconception is that LPP is contagious or caused by poor hygiene. It is neither. The disease is an immune-mediated process with genetic susceptibility. Shampooing frequency, hair products, and scalp cleanliness do not cause or prevent it, though harsh chemical treatments to the hair could theoretically aggravate active inflammation.
Third, people sometimes assume that because the scarring is permanent, treatment is pointless. Treatment cannot undo existing scars, but it can stop the scarring from spreading. In a condition where every month of uncontrolled inflammation means more permanent follicle loss, the difference between treated and untreated disease can be the difference between a few small patches and widespread baldness. Starting treatment as soon as the diagnosis is confirmed gives the best chance of preserving hair long-term.
The Microbiome Connection
Research into whether the scalp’s microbial community plays a role in LPP is at a very early stage but has produced intriguing leads. The first dedicated biopsy-level study of the LPP scalp microbiome found that certain bacterial families on the scalp correlated negatively with key inflammatory signaling molecules involved in the T-cell attack on follicles.30PubMed Central. Lichen Planopilaris: The first biopsy layer microbiota inspection In plain terms, where certain bacteria were less abundant, inflammatory signals were higher. This does not prove that microbial loss causes the inflammation. It could easily be the reverse, with inflammation making the scalp inhospitable to those bacteria. But it opens the door to the possibility that interventions targeting microbial balance could someday complement standard immunomodulatory treatment. For now, no probiotic or microbiome-targeted therapy has been validated for LPP in clinical trials.